JP6814133B2 - キトサンを含む加熱殺菌された製剤及びその調製方法 - Google Patents

キトサンを含む加熱殺菌された製剤及びその調製方法 Download PDF

Info

Publication number
JP6814133B2
JP6814133B2 JP2017515799A JP2017515799A JP6814133B2 JP 6814133 B2 JP6814133 B2 JP 6814133B2 JP 2017515799 A JP2017515799 A JP 2017515799A JP 2017515799 A JP2017515799 A JP 2017515799A JP 6814133 B2 JP6814133 B2 JP 6814133B2
Authority
JP
Japan
Prior art keywords
chitosan
composition
glycerol
present
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533186A5 (OSRAM
JP2017533186A (ja
Inventor
ヨランダ ボッシー，レイラ
ヨランダ ボッシー，レイラ
ナポリ，アレッサンドロ ダイ
ナポリ，アレッサンドロ ダイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Medidom SA
Original Assignee
Laboratoire Medidom SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Medidom SA filed Critical Laboratoire Medidom SA
Publication of JP2017533186A publication Critical patent/JP2017533186A/ja
Publication of JP2017533186A5 publication Critical patent/JP2017533186A5/ja
Application granted granted Critical
Publication of JP6814133B2 publication Critical patent/JP6814133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/05—Alcohols; Metal alcoholates
    • C08K5/053—Polyhydroxylic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/719—Pullulans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/12—Amylose; Amylopectin; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/10—Transparent films; Clear coatings; Transparent materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/54—Aqueous solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017515799A 2014-10-29 2015-10-28 キトサンを含む加熱殺菌された製剤及びその調製方法 Active JP6814133B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/073246 2014-10-29
PCT/EP2014/073246 WO2016066195A1 (en) 2014-10-29 2014-10-29 Heat-sterilized formulation comprising chitosan and process of preparation thereof
PCT/IB2015/058300 WO2016067210A1 (en) 2014-10-29 2015-10-28 Heat-sterilized formulation comprising chitosan and process of preparation thereof

Publications (3)

Publication Number Publication Date
JP2017533186A JP2017533186A (ja) 2017-11-09
JP2017533186A5 JP2017533186A5 (OSRAM) 2018-12-06
JP6814133B2 true JP6814133B2 (ja) 2021-01-13

Family

ID=51842529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515799A Active JP6814133B2 (ja) 2014-10-29 2015-10-28 キトサンを含む加熱殺菌された製剤及びその調製方法

Country Status (17)

Country Link
US (1) US10493155B2 (OSRAM)
EP (1) EP3212166B1 (OSRAM)
JP (1) JP6814133B2 (OSRAM)
KR (1) KR102421423B1 (OSRAM)
CN (1) CN107075174B (OSRAM)
CA (1) CA2965447C (OSRAM)
CO (1) CO2017003840A2 (OSRAM)
DK (1) DK3212166T3 (OSRAM)
ES (1) ES2857273T3 (OSRAM)
HR (1) HRP20201995T1 (OSRAM)
HU (1) HUE053432T2 (OSRAM)
MX (1) MX383011B (OSRAM)
PT (1) PT3212166T (OSRAM)
RS (1) RS61214B1 (OSRAM)
RU (1) RU2712271C2 (OSRAM)
SI (1) SI3212166T1 (OSRAM)
WO (2) WO2016066195A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
AU2017250509B2 (en) 2016-04-14 2023-03-02 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
US11452783B2 (en) * 2017-02-14 2022-09-27 Gi Supply Tissue stain and use thereof
WO2020208418A1 (en) 2019-04-12 2020-10-15 Azura Ophthalmics Ltd. Compositions and methods for the treatment of contact lens discomfort
WO2021092619A1 (en) 2019-11-04 2021-05-14 Covidien Lp Systems and methods for treating aneurysms
JP7453036B2 (ja) * 2020-03-30 2024-03-19 株式会社ナリス化粧品 皮膚外用剤
CN114652866A (zh) * 2020-12-23 2022-06-24 上海其胜生物制剂有限公司 一种羧甲基几丁质溶液的湿热灭菌方法
US12364793B2 (en) 2021-03-16 2025-07-22 Covidien Lp Injectable biopolymer compositions and associated systems and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
JPS6462302A (en) * 1987-09-01 1989-03-08 Nippon Suisan Kaisha Ltd Water-soluble chitosan salt and production thereof
JPH06107551A (ja) * 1992-09-30 1994-04-19 Hisamitsu Pharmaceut Co Inc 関節症治療剤
JPH07118304A (ja) * 1993-10-27 1995-05-09 Asahi Glass Co Ltd キトサン水溶液
US5420197A (en) * 1994-01-13 1995-05-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
WO1997007139A2 (en) 1995-08-17 1997-02-27 Novartis Ag Stabilized chitin derivative compounds
EP1128809B1 (en) * 1998-11-20 2004-12-29 Laboratoire Medidom S.A. Aqueous ophthalmic formulations comprising chitosan
JP5116129B2 (ja) * 2000-09-01 2013-01-09 日本水産株式会社 中性付近のキトサン水溶液の製造法
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
JP5102435B2 (ja) * 2002-10-08 2012-12-19 株式会社リコム キトサン含有多糖、その製造方法及び用途
WO2007073749A1 (en) * 2005-12-23 2007-07-05 Laboratoire Medidom S.A. Thermosetting neutralized chitosan composition forming a hydrogel, lyophilizate, and processes for producing the same
US9034348B2 (en) * 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
US20090142292A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For The Mitigation of Symptoms of Dry Eye

Also Published As

Publication number Publication date
HUE053432T2 (hu) 2021-07-28
DK3212166T3 (da) 2021-02-22
MX383011B (es) 2025-03-13
SI3212166T1 (sl) 2021-01-29
EP3212166A1 (en) 2017-09-06
RU2017118261A3 (OSRAM) 2019-04-25
WO2016067210A1 (en) 2016-05-06
CO2017003840A2 (es) 2017-04-28
RU2712271C2 (ru) 2020-01-28
CA2965447C (en) 2022-05-31
RU2017118261A (ru) 2018-11-29
ES2857273T3 (es) 2021-09-28
CA2965447A1 (en) 2016-05-06
PT3212166T (pt) 2021-02-09
KR20170076659A (ko) 2017-07-04
US10493155B2 (en) 2019-12-03
WO2016066195A1 (en) 2016-05-06
HRP20201995T1 (hr) 2021-02-05
BR112017008353A2 (pt) 2017-12-19
CN107075174A (zh) 2017-08-18
CN107075174B (zh) 2021-03-30
JP2017533186A (ja) 2017-11-09
US20170312364A1 (en) 2017-11-02
EP3212166B1 (en) 2020-12-02
KR102421423B1 (ko) 2022-07-15
RS61214B1 (sr) 2021-01-29
MX2017004760A (es) 2017-07-26

Similar Documents

Publication Publication Date Title
EP3212166B1 (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof
US7902171B2 (en) Composition for treating inflammatory diseases
EP3295943B1 (en) Aqueous suspension agent comprising glucocorticosteroid nanoparticles
US9012396B2 (en) Use of lipid conjugates in the treatment of conjunctivitis
FR2579895A1 (OSRAM)
Anna et al. Pharmacological and biological effects of chitosan
CN101501075B (zh) 支化透明质酸和制造方法
Matica et al. TOXICITY OF CHITOSAN BASED PRODUCTS.
CA3002384A1 (en) Pharmaceutical formulations that form gel in situ
JP2017533186A5 (OSRAM)
Pal et al. Chitosan: as highly potential biopolymer obtainable in several advance drug delivery systems including biomedical applications
Stefan et al. The current view on biological potency of cationically modified chitosan
Lu et al. Enhanced antibacterial and antibiofilm activities of quaternized ultra-highly deacetylated chitosan against multidrug-resistant bacteria
WO2000030609A1 (en) Aqueous ophthalmic formulations comprising chitosan
JP3050898B2 (ja) 水性医薬製剤
HK1238537B (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof
HK1238537A1 (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof
CN109152793B (zh) 免疫学产品
BR112017008353B1 (pt) Formulação termoesterilizada compreendendo quitosana e processo de preparação da mesma
US11376274B2 (en) Joint cavity injection preparation and use thereof
EP4667000A1 (en) Hyperosmolar ophthalmic composition comprising carboxymethyl chitosan
FR2690450A1 (fr) Dérivés d'acide undécylénique avec des macromolécules hydrophiles et utilisations en cosmétique ou en pharmacie.
Elçin Panomycocin-incorporated chitosan-tpp nanoparticles: preparation, characterization and in vitro determination of antifungal activity against human dermatophytes
Nandyala et al. Entomological and marine sources of chitosan: A review of its properties and biopolymer applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201218

R150 Certificate of patent or registration of utility model

Ref document number: 6814133

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250